| 1444 |
National Cancer Institute |
Html |
en |
Adult Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of adult acute myeloid leukemia. |
| characteristic genetic abnormalities | 0.39234 |
| Adult Acute Myeloid | 0.42781 |
| acute myelogenous leukemia | 0.488829 |
| acute biphenotypic leukemia | 0.454638 |
| Acute myeloblastic leukemia | 0.474183 |
| acute erythroblastic leukemia | 0.447971 |
| monoblastic leukemia antigens | 0.403407 |
| transient leukemia | 0.398296 |
| Leukemia Group | 0.421425 |
| acute eosinophilic leukemia | 0.464145 |
| acute leukemias | 0.416535 |
| biphenotypic acute leukemia | 0.461147 |
| acute monocytic leukaemia | 0.396733 |
| chronic myeloid leukemia | 0.484726 |
| chronic myelomonocytic leukemia | 0.40262 |
| AML | 0.598074 |
| World Health Organization | 0.418965 |
| Health Organization Classification | 0.417813 |
| acute monocytic leukemia | 0.541741 |
| minimally differentiated AML | 0.404409 |
| acute erythroid leukemias. | 0.391545 |
| acute leukemia patients | 0.46612 |
| blast percentage | 0.399782 |
| myelodysplastic syndromes | 0.404558 |
| et al. | 0.486443 |
|
| lineage acute leukemia | 0.472137 |
| acute megakaryoblastic leukemia | 0.570037 |
| acute biphenotypic leukaemia | 0.396849 |
| internal tandem duplication | 0.391126 |
| Br J Haematol | 0.407064 |
| acute monoblastic leukemia | 0.552455 |
| adult megakaryoblastic leukemia | 0.392499 |
| acute myeloid leukemia | 0.936356 |
| acute myeloid leukaemia | 0.463297 |
| acute myelomonocytic leukemia | 0.509496 |
| genetic abnormalities | 0.393333 |
| acute megakaryocytic leukemia | 0.467082 |
| differential diagnosis | 0.419864 |
| cases | 0.405688 |
| Abstract | 0.458712 |
| pure erythroid leukemia | 0.448165 |
| cytochemical features | 0.408002 |
| acute erythroid leukemia | 0.471063 |
| bone marrow | 0.469209 |
| acute erythroid leukemias | 0.400236 |
| acute promyelocytic leukemia | 0.615165 |
| acute nonlymphocytic leukemia | 0.489262 |
| acute lymphoblastic leukemia | 0.489649 |
| acute leukemia | 0.565771 |
|
CLICK HERE |
| 1539 |
National Cancer Institute |
Html |
en |
Adult Primary Liver Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of adult primary liver cancer. |
| Adult liver cancer | 0.3229 |
| bile duct cancer | 0.289957 |
| cancer spreads | 0.268265 |
| body | 0.335412 |
| healthy liver tissue | 0.301199 |
| PDQ cancer information | 0.323551 |
| clinical trial search | 0.281007 |
| clinical trials | 0.55174 |
| cancer information summary | 0.30136 |
| adult primary liver | 0.896168 |
| clinical trial | 0.389615 |
| liver disease | 0.276306 |
| detailed pictures | 0.294233 |
| healthy donated liver | 0.285489 |
| treatment clinical trial | 0.264079 |
| body radiation therapy | 0.304178 |
| NCI PDQ cancer | 0.273742 |
| malignant tumor cells | 0.27026 |
| Duct Cancer Treatment | 0.289551 |
| radiation therapy | 0.397919 |
| Childhood Liver Cancer | 0.337182 |
| entire liver | 0.272876 |
| general cancer information | 0.265929 |
| treatment | 0.426881 |
| liver injury | 0.286661 |
|
| hepatic portal vein | 0.283724 |
| Clinic Liver Cancer | 0.322316 |
| metastatic liver cancer | 0.323102 |
| nearby healthy tissue | 0.265169 |
| NCI-supported cancer | 0.264234 |
| cancer cells | 0.36535 |
| hepatic artery | 0.317753 |
| primary liver cancer | 0.97153 |
| Cancer Information Service | 0.266321 |
| specific cancer cells | 0.265527 |
| Liver Cancer Treatment | 0.368965 |
| patient | 0.265351 |
| treatment clinical trials | 0.285012 |
| National Cancer Institute | 0.332241 |
| stereotactic body radiation | 0.30319 |
| liver transplant | 0.296023 |
| new treatment | 0.282659 |
| external radiation therapy | 0.294036 |
| blood | 0.29169 |
| PDQ summary | 0.268144 |
| cancer clinical trials | 0.30738 |
| tumor | 0.3047 |
| cancer information summaries | 0.264877 |
| comprehensive cancer information | 0.264661 |
|
CLICK HERE |
| 1634 |
National Cancer Institute |
Html |
en |
Hydrazine Sulfate (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of hydrazine sulfate as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| randomized controlled trials | 0.450078 |
| treatment | 0.522727 |
| cancer treatment | 0.475015 |
| cancer prevention | 0.44047 |
| Complementary Therapies Editorial | 0.452982 |
| United States | 0.440744 |
| Drug Administration | 0.454034 |
| Cancer Information Specialist | 0.44699 |
| cancer cells | 0.451523 |
| Cancer Information Service | 0.478296 |
| hydrazine compounds | 0.44033 |
| PDQ cancer information | 0.502287 |
| Cancer Complementary | 0.451114 |
| body weight | 0.443552 |
| hydrazine sulfate treatment | 0.519798 |
| preclinical studies | 0.453016 |
| CAM therapies | 0.439277 |
| treatment clinical trials | 0.44455 |
| National Cancer Institute | 0.557582 |
| studies | 0.47528 |
| clinical trials | 0.59962 |
| colon cancer patients | 0.451298 |
| alternative medicine | 0.474569 |
| conventional treatment | 0.441057 |
|
| cancer information summary | 0.479257 |
| alternative cancer therapies | 0.448575 |
| Federal Trade Commission | 0.442333 |
| National Institutes | 0.438958 |
| clinical trial | 0.445969 |
| lung cancer patients | 0.451382 |
| CAM cancer research | 0.443791 |
| nutritional status | 0.439129 |
| breast cancer prevention | 0.438548 |
| advanced cancer | 0.438703 |
| patients | 0.50459 |
| cancer patients | 0.480463 |
| Cancer Care page | 0.43981 |
| health | 0.440064 |
| hydrazine sulfate | 0.914395 |
| PDQ summary | 0.439248 |
| NCI PDQ cancer | 0.463099 |
| cancer information database | 0.449512 |
| effects | 0.440229 |
| alternative therapies | 0.459489 |
| cancer information summaries | 0.449727 |
| Therapies Editorial Board | 0.445847 |
| randomized clinical trials | 0.444095 |
|
CLICK HERE |
| 1660 |
National Cancer Institute |
Html |
en |
Liver (Hepatocellular) Cancer Screening (PDQ®)–Patient Version |
Expert-reviewed information summary about tests used to detect or screen for liver (hepatocellular) cancer. |
| PDQ Screening | 0.551346 |
| hepatocellular) cancer: | 0.719756 |
| cancer treatment | 0.490974 |
| cancer screening methods | 0.577774 |
| United States | 0.488028 |
| ongoing clinical trials | 0.569331 |
| routine screening tests | 0.542104 |
| Abnormal screening results | 0.526706 |
| following PDQ summaries | 0.569947 |
| Cancer Information Service | 0.537158 |
| PDQ cancer information | 0.763376 |
| false-negative test result | 0.487695 |
| widely used tumor | 0.492628 |
| common cancer | 0.497307 |
| Prevention Editorial Board | 0.554017 |
| treatment clinical trials | 0.497409 |
| National Cancer Institute | 0.639479 |
| clinical trials | 0.758209 |
| early detection | 0.490925 |
| PDQ documents | 0.509492 |
| test result | 0.528806 |
| cancer information summary | 0.632034 |
| new treatment | 0.500882 |
| breast cancer prevention | 0.517023 |
|
| diagnostic tests | 0.505464 |
| test results | 0.489974 |
| Cancer screening trials | 0.585626 |
| tumor markers | 0.491268 |
| NCI website | 0.503158 |
| false-positive test result | 0.487287 |
| cancer patients | 0.48575 |
| Cancer Care page | 0.521215 |
| PDQ database | 0.515283 |
| latest published information | 0.502276 |
| specific tumor marker | 0.485952 |
| NCI’s PDQ | 0.524006 |
| risk factor | 0.495527 |
| PDQ summary | 0.551372 |
| liver biopsy | 0.551147 |
| cancer symptoms | 0.506472 |
| NCI PDQ cancer | 0.600996 |
| Chinese American men | 0.489845 |
| tests | 0.559642 |
| cancer information summaries | 0.546479 |
| comprehensive cancer information | 0.546147 |
| cancer | 0.936669 |
| liver cancer | 0.793964 |
|
CLICK HERE |
| 1874 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores extragonadales de células germinativas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores extragonadales de células germinativas. |
| germ-cell tumors | 0.383819 |
| metastatic germ | 0.316138 |
| germ-cell tumors with | 0.328427 |
| residual mass | 0.330871 |
| Nichols CR | 0.459486 |
| Greco FA | 0.321626 |
| initial salvage therapy | 0.319174 |
| largo plazo | 0.317683 |
| following systemic chemotherapy | 0.321834 |
| with germ-cell tumors | 0.328027 |
| malignant germ-cell tumors | 0.322658 |
| single-institution experience with | 0.326215 |
| unknown primary site | 0.318402 |
| germ cell tumours | 0.337125 |
| Extragonadal germ | 0.317435 |
| Cell Cancer Collaborative | 0.335481 |
| Hainsworth JD | 0.322365 |
| cell or non-germ | 0.330347 |
| Williams SD | 0.32023 |
| salvage treatment | 0.337434 |
| high-dose chemotherapy | 0.334497 |
| Instituto Nacional | 0.329901 |
| International Germ Cell | 0.371979 |
| Tumores mixtos | 0.340879 |
| Advanced poorly differentiated | 0.316704 |
|
| cell malignancy after | 0.327663 |
| primary mediastinal nonseminomatous | 0.349396 |
| unrecognized germ | 0.316359 |
| patients with | 0.426473 |
| Kramar A | 0.320119 |
| germ cell neoplasms | 0.33799 |
| disseminated germ | 0.332449 |
| Einhorn LH | 0.38746 |
| Germ Cell Consensus | 0.341019 |
| effective chemotherapy regimen | 0.321136 |
| Salvage chemotherapy | 0.319709 |
| germ cell | 0.988418 |
| PDQ Tratamiento | 0.334355 |
| extragonadal nonseminomatous germ | 0.321388 |
| Indiana University | 0.317574 |
| Clin Oncol | 0.830939 |
| as salvage treatment | 0.323614 |
| mediastinal germ-cell tumors | 0.323089 |
| mediastinal nonseminomatous germ | 0.353563 |
| postchemotherapy residual mass | 0.322319 |
| germ cell tumors | 0.75596 |
| Catalano PJ | 0.324048 |
| Oncology Group | 0.318284 |
| germ cell cancer | 0.426267 |
|
CLICK HERE |
| 1930 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de células de transición de pelvis renal y de uréter (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de células de transición de pelvis renal y de uréter. |
| PDQ Tratamiento | 0.301965 |
| siguientes procedimientos | 0.300864 |
| presente sección | 0.300329 |
| tinte circula | 0.300646 |
| siguientes aspectos | 0.30066 |
| Physician Data Query | 0.300636 |
| estadio i | 0.300593 |
| estadio ii | 0.300585 |
| túbulos renales | 0.300794 |
| rayos x | 0.301624 |
| sistema urinario masculino | 0.301197 |
|
| vejiga almacena | 0.301076 |
| ondas sonoras | 0.300597 |
| National Cancer Institute | 0.30009 |
| células renales | 0.304024 |
| siguientes riesgos | 0.300073 |
| pelvis renal | 0.995929 |
| materiales plásticos | 0.300686 |
| siguientes pruebas | 0.30061 |
| siguientes estadios | 0.301441 |
| Instituto Nacional | 0.300663 |
|
CLICK HERE |
| 2117 |
National Cancer Institute |
Html |
es |
Brotes de cáncer |
Hoja informativa que describe lo que es un brote de cáncer, el proceso para notificar e investigar brotes sospechosos y los retos en la investigación de brotes sospechosos. |
| Seguridad Ocupacional | 0.284426 |
| posibles carcinógenos | 0.307688 |
| múltiples tipos | 0.294654 |
| Centro Nacional | 0.429489 |
| Health Consultations. | 0.283346 |
| cabo programas | 0.28293 |
| Sustancias Tóxicas | 0.544168 |
| Public Health Assessments | 0.353028 |
| ambiente causantes | 0.320442 |
|
| Salud Ambiental | 0.29888 |
| Estados Unidos | 0.297229 |
| Medicina Ocupacional | 0.42476 |
| claro exceso | 0.319927 |
| cabo evaluaciones | 0.29639 |
| Cáncer usa datos | 0.931444 |
| contaminante ambiental | 0.520538 |
| contaminante sospechoso | 0.478153 |
|
CLICK HERE |
| 14597 |
National Cancer Institute |
Html |
en |
Common Cancer Myths and Misconceptions |
The latest science-based information concerning some common misconceptions about cancer. Learn the facts to worry less and make good health decisions. |
| cancer treatment | 0.293552 |
| multiple family members | 0.287169 |
| different surgical tools | 0.292574 |
| best studies | 0.351264 |
| wrong ideas | 0.256786 |
| individual cancer patient | 0.352232 |
| Cancer patients | 0.292909 |
| artificial sweeteners | 0.340098 |
| Cancer Vaccines | 0.299159 |
| bladder cancer | 0.291637 |
| good prevention | 0.259057 |
| Cancer Risk | 0.329552 |
| tobacco smoke | 0.287568 |
| environmental factors | 0.290117 |
| Risk Factors | 0.292696 |
| magnetic energy | 0.286101 |
| complementary therapies | 0.281474 |
| person | 0.354916 |
| cancers | 0.347867 |
| Five-year survival rates | 0.302006 |
| common cancer myths | 0.360301 |
| Metastatic Cancer | 0.322576 |
| Annual Report | 0.258223 |
| NCI fact sheet | 0.996571 |
| United States | 0.312478 |
|
| excess weight gain | 0.296228 |
| cancer cells | 0.333742 |
| 5-year survival rate | 0.300282 |
| Helicobacter pylori | 0.298521 |
| personal hair dye | 0.285054 |
| natural result | 0.291706 |
| Hereditary Cancer Syndromes | 0.328419 |
| cell phones | 0.296722 |
| scientific evidence | 0.293613 |
| No. Researchers | 0.257042 |
| needless worry | 0.25947 |
| old theories | 0.256313 |
| transplant-related cancer | 0.304436 |
| NCI fact sheets | 0.326267 |
| Botanicals/Herbal Products section | 0.288672 |
| No. | 0.263456 |
| Breast Cancer | 0.289863 |
| medicine products—including vitamins | 0.287253 |
| latest science-based information | 0.32382 |
| power lines | 0.324548 |
| thyroid cancers | 0.300398 |
| Certain popular ideas | 0.304234 |
| cancer | 0.824886 |
| information | 0.40326 |
|
CLICK HERE |
| 15636 |
National Cancer Institute |
Html |
null |
Step 6: Post-Award Administration |
Information on numerous requirements that must be met in order to to be in compliance with NIH policy after receiving an award. This includes implementing monitoring systems and keeping financial and programmatic records. |
|
|
CLICK HERE |
| 16448 |
National Cancer Institute |
Html |
en |
Identifying Novel Drug Combinations to Overcome Treatment Resistance |
A review of current research identifying and testing drug combination approaches that have the potential to overcome or delay resistance to cancer treatment. |
| cancer treatment | 0.25347 |
| cancer cell lines—a | 0.280999 |
| healthy cells | 0.296062 |
| novel drug combinations | 0.308632 |
| lung cancer | 0.280527 |
| chemotherapy resistance | 0.310051 |
| cancer drug resistance | 0.46496 |
| Kettering Cancer Center | 0.280587 |
| effective drug pairs | 0.26607 |
| clinical trials | 0.313646 |
| epigenetic alterations | 0.2886 |
| original drug | 0.25941 |
| molecular alterations | 0.297668 |
| myeloid cells | 0.309525 |
| ovarian cancer | 0.356692 |
| cisplatin resistance | 0.289204 |
| patients | 0.50622 |
| immune checkpoint inhibitors | 0.342594 |
| single tumor | 0.262236 |
| Nature Reviews Cancer | 0.299509 |
| potential drug combinations | 0.282064 |
| tumor—contain molecular alterations | 0.269672 |
| combination treatment approach | 0.285984 |
| multidrug resistance section | 0.355811 |
| drug resistance | 0.805264 |
|
| cancer drugs | 0.296242 |
| treatment | 0.450602 |
| Cancer Research UK | 0.305072 |
| ABC transporter inhibitors | 0.39367 |
| chemotherapy drugs | 0.281313 |
| breast cancer tumors | 0.293816 |
| cancer cells | 0.926321 |
| cancer cell lines | 0.386565 |
| so-called intrinsic resistance | 0.362006 |
| epigenetic alteration | 0.261391 |
| Dana-Farber Cancer Institute | 0.280545 |
| Dr. Gottesman | 0.323556 |
| DNA methylation | 0.280984 |
| Cancer Research | 0.350827 |
| ABC transporters | 0.47073 |
| Hospital Cancer Center | 0.277242 |
| epigenetic codes—molecular modifications | 0.267446 |
| cancer researchers | 0.266263 |
| inactivating T cells | 0.270905 |
| drugs | 0.323984 |
| ovarian cancer cell | 0.296997 |
| drug combinations | 0.458324 |
| tumor microenvironment | 0.309626 |
| lung cancer cell | 0.275824 |
|
CLICK HERE |